New radiotherapy approach for advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates a novel treatment method called heterogeneously hypofractionated radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) who cannot undergo standard chemoradiotherapy. The study aims to assess both the effectiveness and safety of this treatment option, which is designed to minimize damage to healthy tissue while providing adequate control of the cancer. Patients are categorized based on their ability to tolerate standard treatment, allowing for a tailored approach to their care. The goal is to improve survival rates and quality of life for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytological confirmed locally advanced, inoperable NSCLC.
* Age ≥18 years.
* Signed informed consent.
* Performance status 0-2.
* Able to comply with study and follow-up procedures.
* Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch for the duration of study treatment and one month thereafter.

Exclusion Criteria:

* Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
* Dose plan conforming to protocol planning criteria not possible.
* Uncontrolled metastatic disease.
* Other active malignant disease.

Where it's running

• Aarhus University Hospital
  Aarhus, Denmark Recruiting

Study contacts

• Principal investigator: Azza A Khalil, MD, PhD — Aarhus University Hospital
• Study coordinator: Azza A Khalil, MD, PhD
• Email: azzakhal@rm.dk
• Phone: +4578462556

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

• Infusion of IOV-4001 for advanced melanoma and lung cancer

  This study is testing a new treatment called IOV-4001 to see if it can help adults with advanced melanoma and lung cancer by targeting and killing their tumor cells.

  Recruiting at 10 sites Phase 1/2 Iovance Biotherapeutics, Inc. · Los Angeles, California and 10 other locations · NCT05361174

• Self‑manual lymph drainage for head and neck lymphedema

  This trial will test whether different intensities of self‑applied manual lymph drainage help people with head and neck lymphedema after radiotherapy for oropharyngeal cancer.

  Recruiting Lund University · Lund, Skåne County · NCT07215169

• Health-Oriented Protocol for Epidermal Radiodermatitis

  This study looks at how skin reactions from radiation therapy affect adults with head/neck or pelvic cancers and whether certain factors influence RID outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07129525

• Skipping the clinical target volume (CTV) around the primary tumor in limited-stage small cell lung cancer

  This trial tests whether giving chest radiotherapy that skips the usual extra margin around the main tumor is as effective and causes fewer side effects for people with limited-stage small cell lung cancer who have responded to initial chemotherapy.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07008716

• Curative chest re‑irradiation for thoracic cancers

  This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.

  Recruiting University of Aarhus · Aarhus, Jutland · NCT06950073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.